Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Shen-Yung Wang

Clin Mol Hepatol. 2023;29(2):349-351. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0082

View: 2644 Download: 62

Tung-Hung Su, Chih-Horng Wu, Tsung-Hao Liu, Cheng-Maw Ho, Chun-Jen Liu

Clin Mol Hepatol. 2023;29(2):230-241. Published online January 30, 2023

DOI: https://doi.org/10.3350/cmh.2022.0421

View: 5844 Download: 372 Web of Science: 9 Crossref: 10

Dorothy Cheuk-Yan Yiu, Huapeng Lin, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Ken Liu, Terry Cheuk-Fung Yip

Received April 18, 2024 Accepted July 4, 2024

DOI: https://doi.org/10.3350/cmh.2024.0280 [Accepted]

View: 179 Download: 19

1 |

Viewed By 5665	MAFLD: How is it different from NAFLD?
Viewed By 5580	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5387	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5338	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4992	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 176	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 119	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 113	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 91	MAFLD: How is it different from NAFLD?
Cited By 82	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search